Professor Joly is an internationally acclaimed figure in health law, intellectual property, and bioethics, leaving an enduring impact on the ethical landscape of modern medicine. With pivotal roles in the International Cancer Genome Consortium (ICGC) and the International Human Epigenome Consortium (IHEC), he has spearheaded the development and implementation of controlled access mechanisms in genomics research since 2009, influencing emerging models worldwide. With over 120 peer-reviewed publications, influential book chapters, and recognition such as the "Innovation Merit" award from the Quebec Bar, his influence extends to legal, ethical, and scientific domains. Testifying before esteemed bodies like the Council of Europe and the Canadian Senate, his expertise shapes genetic discrimination discourse. Inducted into the Canadian Academy of Health Sciences (CAHS), his current research navigates the intricate interplay of scientific knowledge, health law, and bioethics at the forefront of biotechnology and emerging health technologies.
Podden och tillhörande omslagsbild på den här sidan tillhör Mike Kaz. Innehållet i podden är skapat av Mike Kaz och inte av, eller tillsammans med, Poddtoppen.
